Diagnosis of type 2 diabetes according to the World Health Organization definition.
Current treatment with a SGLT2-I1 at maximally tolerated dose.
Current treatment with an ACE inhibitor or an ARB1 at maximally tolerated dose.
Plasma potassium level of 4.8 mmol/L or less at the time of screening.
CKD defined as eGFR ≥25 ml/min/1.73 m2 and albuminuria (UACR between 30-5000 mg/g).
Speak and understand Danish fluently.
You may not be if
Inability to give informed consent.
Severe renal disease with eGFR \<25 ml/min/1.73m2.
Severe hepatic disease (plasma ALAT above 3 x upper limit of normal).
Active cancer diagnosis other than basal cell carcinoma.
Treatment with systemic steroids at time of randomization.
Bariatric surgery within 2 years or other gastrointestinal surgeries that induce chronic malabsorption.
Alcohol or drug abuse within 3 months of informed consent that would interfere with trial participation or any ongoing condition leading to decreased compliance with study procedures or study drug intake.
Chronic or acute pancreatitis.
Pregnancy or breastfeeding (see pregnancy below).
Poorly controlled medical condition, e.g. congestive heart failure (New York Heart Association III-IV or EF ≤ 40%), recent (within 3 months) stroke or acute myocardial infarction or any other condition that in the opinion of the investigator will put the trial participant at risk if participating in the trial.
Allergy to finerenone or any of the excipients contained in the drug.
Current systemic treatment with strong inhibitors of CYP3A4 (e.g. itraconazol, ketoconazole, ritonavir, cobicistat, clarithromycin) or strong inducers of CYP3A4 (e.g. rifampicin, carbamazepine, phenytoin, phenobarbital).
Current treatment with other MRAs (e.g. spironolactone, eplerenone etc.).
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose- galactose malabsorption.
